Dupilumab (Dupixent, Sanofi) is indicated 'as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP (chronic rhinosinusitis with nasal polyposis) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control'.
The dosage schedule is available in the summary of product characteristics for dupilumab.
Dupilumab costs £1,264.89 per pack of 2 prefilled pens or prefilled syringes (excluding VAT, BNF online accessed July 2025).
The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Sanofi's webpage on sustainability.